Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab in Anterior Stroke With Large Ischemic Core
NCT06437431Phase 3Withdrawn
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Sep 2026
- Primary completion
- Oct 2030
- Modality
- Antibody Fragments
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing glenzocimab with placebo (2 arms). Primary endpoint: Proportion of patients with good functional outcome (mRS 0-3) at 3 months. Planned start Sep 2026; status: withdrawn.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06437431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437431.